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In the Lewis  (Le) 1 rat,  guinea pig (GP) myelin basic protein  (BP) is by far 
the most encephalitogenic species of BP that has been tested  (1,  2).  Recently, 
Chou et al.  (3) have shown that a 19-amino acid fragment of GP BP, peptide C1 
(residues 68-88),  is as active  in the Le rat as the parent protein.  The amino 
acid sequence of this peptide is as follows: 
68  79  88 
NH2-G•y•Ser•Leu-Pr••G•n-Lys-Ser-G•n-Arg•Ser-G•n-Asp-G•u-Asn•Pr•-Va•-Va•-His-Phe-C••H 
(4, 5). 2 Although the rat C1 peptide differs from the GP C1 peptide only by a 
threonine for serine substitution at position 79 (1, 6), rat BP is appreciably less 
active than GP BP in the Le rat.  We have compared,  therefore,  the immune 
response of the Le rat to the two C1 peptides; including their encephalitogenic 
activities,  capacity to stimulate incorporation of [3H]thymidine by lymph node 
cells (LNC), and their capacity to induce the production of antibody. 
Materials and Methods 
Experimental Design.  Female Le rats  were challenged with each of the two C1  peptides, 
respectively, in complete Freund's adjuvant (CFA). Assessment of clinical signs was made daily 
and  some animals  were killed for histology 1-2  days  after  the  peak  of clinical signs.  Other 
animals were sacrificed 8-9 days after challenge and the in vitro response of their LNC to the 
two C1  peptides was determined by the incorporation of [3H]thymidine.  Other groups  of rats 
were bled from the tail at varying intervals aRer challenge through day 35;  they were then 
boostered intraperitoneally (i.p.)  with the respective C1 in incomplete Freund's adjuvant (IFA) 
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NS 10721,  NS 11418,  and  NS  05071  from  the  National  Institute  of  Neurological  and  Communicative 
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Abbreviations used in this paper: BMB, Mycobacterium butyricum; BP, myelin basic protein; 
CI,  residues  68-88  of BP;  CFA,  complete  Freund's  adjuvant;  CM-52, carboxymethylcellulose; 
EAE, experimental allergic encephalomyelitis; GP,  guinea pig; IFA, incomplete Freund's adju- 
vant; i.p.,  intraperitoneally; Le,  Lewis; LNC,  lymph node cells; P1,  residues 43-88  of BP;  SI, 
stimulation index. 
2 The numbering system for bovine BP (4) is used throughout since the complete sequence of 
GP BP is not known. It should be noted that in GP C1 residues 76-77 are deleted. 
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and exsanguinated  13 days later.  Their sera were assayed for antibody by the sodium  sulfate 
method of radioimmunoassay (7). 
Induction  of Experimental Allergic Encephalomyelitis (EAE).  Le  rats  3-6  mo of age  were 
obtained from Microbiological Associates, Bethesda, Md. The appropriate amount of the respec- 
tive C1  peptide was dissolved  in Ringer's solution and homogenized with an equal  volume of 
incomplete adjuvant (Difco Laboratories, Detroit, Mich.) to which crushed, killed Mycobacterium 
butyricum  (BMB)  had  been  added.  Rats  were  lightly  anesthetized  with  ether  and  injected 
intradermally in each of the hind footpads with 0.05 ml of the emulsion, i.e., a total of 0.1 ml/rat. 
The dose of BMB per rat was uniformly 250 /~g. 
Assessment ofEAE.  Clinical signs were graded on a  scale of 1-6 and histological changes on 
a  scale of 1-8, according to criteria previously described (1,  3). 
Preparation of Fragment 43-88 (P1) and Peptide 68-88 (C1).  GP and Wistar rat brains were 
from Pel-Freez Bio-Animals, Inc., Rogers, Ark. BP was prepared from these tissues by previously 
published methods (8).  An acid extract of chloroform/methanol delipidated brain was chromato- 
graphed at 25°C on carboxymethylcellulose (CM-52, H.  Reeve Angel & Co., Inc., Clifton, N. J.) 
using a  linear NaC1 gradient in 0.08 M glycine buffer, pH 10.4, 2 M urea. The last peak to elute 
from the column, component 1 of BP, is considered the native unmodified form of BP and was the 
material used in these studies. By this procedure, the smaller of the two rat basic proteins was 
obtained. 
BP was subjected to limited pepsin (Worthington Biochemical Corp., Freehold, N. J.) digestion 
(9) at pH 3.0 for 1 h at 40°C,  and fragment P1 isolated from the digest as previously described (8). 
The preparation of P1 was contaminated with ~30% fragment 37-88. 
Fragment P1  was subjected to  limited chymotrypsin digestion  (3)  which results in selective 
cleavage at tyrosine 67 and phenylalanine 42.  Peptide C1 was separated from peptides 37-42 and 
43-67 by chromatography on CM-52 using a  linear NaC1 gradient in 0.02 M ammonium acetate, 
pH 4.0, followed by Sephadex G-50 gel filtration. 
Lymphocyte Stimulation.  The response of LNC was determined by modification of a previously 
published method (10).  Rats were killed and their popliteal and inguinal lymph nodes removed 
immediately  under  sterile  conditions  and  teased  apart.  LNC  obtained  in  this  manner  were 
suspended in a medium containing 15% fresh Le rat serum at a concentration of  2.5 × 106 cells/ 
ml and cultured in the presence of the appropriate concentration of antigen. Quadruplicate 
cultures were established for each variable. Incorporation of [Methyl-3H]thymidine was deter- 
mined after  24 and 48 hr incubation. The stimulation index (SI)  was calculated  by dividing the 
mean counts per minute (cpm) of  stimulated cultures  by the mean cpm of  unstimulated cultures. 
In preliminary  experiments,  it was determined that the optimal day after  challenge to obtain 
LNC was one day before the onset of  clinical  signs. 
Radioimmunoassay (RIA).  GP PI and rat P1 (1.0  rag)  were labeled with 1.0 mCi of  carrier- 
free 12SI-Na,  according to the lactoperoxidase method (11).  The labeled fragment was separated 
from free iodide on a Sephadex  G-10 column  (30 ×  0.7 cm inside diameter)  in 0.01 N  HCI. 
Fractions were read at 278 nm and the peak tube, which contained the majority of  the labeled 
fragment, used in RIA. The concentration of  P1 in the peak tube was estimated from a standard 
curve constructed with unlabeled P1. The efficiency  of  labeling was 85-90%. 
Sera were assayed for antibody by the technique of  Day and Pitts  (7).  210/~l of  normal rabbit 
serum (1:3  in 0.01  M  phosphate-buffered saline)  was mixed with 20 ~I of  rat antiserum and 20 #l 
of 125I-P1 for a final concentration of 1 ×  10 -7 M. After 5 min at 25°C,  500 ftl of 1.9 M  Na2SO4  at 
30°C  was added.  After 1 h  the tubes were  centrifuged for 30 min,  the supernate removed and 
discarded,  and the precipitates washed three times each with 500  ~l 1.27 M  NasSO4.  The final 
precipitates  were  dissolved  in  0.01  M  phosphate-buffered  saline  and  transferred  to  counting 
tubes. Percent binding was based on total count tubes (50,000-100,000 cpm) since the percent 12si- 
P1 left in the original tubes, after the precipitates had been transferred, was <1.0% of the total. 
Percent binding was converted to picomol antigen bound/milliliter of serum. All sera were tested 
in triplicate and agreement was within 5% of the mean.  Normal and adjuvant control rat sera 
bound <10 pmol P1/ml. 
Results 
Encephalitogenic  Activity.  The  encephalitogenic  activity  of  the  two  C1 
peptides  is  shown  in  Table  I.  Four quantitative  criteria  of encephalitogenic KIBLER,  FRITZ,  CHOU,  CHOU,  PEACOCKE,  BROWN,  AND  McFARLIN 
TABLE  I 
Encephalitogenic Activity of Cl (68-88) 
1325 
Challenge  EAE 
Maximal  Histology 
Dose (10  -4  Source  N*  Day of  onset  clinical 
~mol)  grades  grades§ 
25011  GP  4/4  9.4  5.5  3.5 
250  Rat  4/4  10.8  4.8  3.0 
25  GP  4/4  9.2  5.4  3.1 
25  Rat  4/4  11.0  4.5  3.2 
15  Rat  3/4  11.6  4.3  3.2 
7.5  Rat  1/4  (12)  (4.5)  3.3 
2.5  GP  4/4  10.3  5.8  3.3 
2.5  Rat  0/4  -  - 
0.25  GP  4/4  12.2  5.0  2.5 
0.15  GP  4/4  13.2  4.8  3.2 
0.075  GP  2/4  14.0  5.0  2.0 
0.025  GP  0/4  -  - 
* Ratio number rats  with EAE to number challenged.  Each rat received  250/~g BMB. 
S Scale  of  1-6;  1-limp tail,  6 moribund. 
§ Rats  killed  I-2 days after  peak of  clinical  disease.  Scale  of  0-8, 1  -minimal lesions,  8 extensive 
in all  areas of  central  nervous system. 
H  250 × 10  -4 ~mol ~  50 ~g. 
potency were used; number of animals which developed EAE out of the number 
challenged  (N),  day  of onset,  and  the  clinical  and  histological  grades.  The 
data shown in Table I  are representative of a  number of experiments.  EAE in 
the Le rat is a highly reproducible phenomenon and the results among different 
experiments were  almost identical.  The  minimal encephalitogenic  dose of GP 
C1  was 0.075  ×  10 -4  ~mol (15 ng); for rat C1 the minimal dose was 7.5  ×  10 -4 
~mol (1,500 ng).  Neither peptide produced disease in all animals at these dose 
levels, but GP C1  at 0.15  (30 ng) and rat C1 at 15  (3,000 ng)  x  10 -4  #mol had 
good activity as judged by the various quantitative parameters. 
Lymphocyte Stimulation.  LNC were harvested from rats  (six per group) 8 
days after challenge with  GP C1  and 9 days after challenge with rat C1.  LNC 
from both groups of rats were incubated in the presence of 25  ×  10 -4  ~mol/ml 
of GP and rat C1.  As shown in Table II, LNC from rats challenged with 25  x 
10 -4 ~mol of GP C1 gave a  mean SI of 4.7  (range of 4.0-5.4)  in the presence of 
GP C1  and a  mean SI of 2.1  (range of 2.0-2.2)  in the presence of rat C1.  LNC 
from rats  challenged  with  25  ×  10 -4  gmol  of rat  C1  gave  SI  which  were  of 
borderline significance (not shown in Table II). LNC from rats receiving 250  × 
10 -4  ~mol of rat  C1  (Table II) gave a  mean  SI of 2.6  (range  of 2.4-3.0)  in the 
presence of GP C1  and a  mean SI of 2.0  (range  1.9-2.1)  in the  presence of rat 
C1. These experiments have been repeated with similar results. 
Fig. I shows typical in vitro dose-response curves of LNC from rats challenged 
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TAB~  II 
In Vitro LNC Responses* 
Stimulant (10  -4 #tool/ 
ml) 
SIg of  LNC from rats challenged with: 
GP Cl (25 x  10  -4  Rat CI (250 x  10  -4 
~mol)  /~mol) 
GP C1  25  4.7 (4.0-5.4)  2.6 (2.4-3.0) 
Rat C1  25  2.1 (2.0-2.2)  2.0 (1.9-2.1) 
* [3H]Thymidine  incorporation of LNC  from groups of six rats each 
challenged with the respective  Cl. Cells  were harvested 8 (GP) and 9 
(rat)  days after  challenge. 
SI-mean cpm of stimulated cultures/mean cpm of unstimulated cul- 
tures (quadruplicates).  An SI >  1.5 is significant. 
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Fla. I.  In vitro  stimulation of  LNC from rats 8 days after  challenge with 25 x 10  -4 #mol 
GP  CI (A) and 9 days after challenge  with 250  x  10  -4 /~mol rat Cl (B). Cells were 
incubated with 2.5-125 x 10  -4 ~mol of  GP BP (©) and rat BP (0),  respectively,  per ml of 
culture medium.  Stimulation  indices not shown at 2.5 x  10  -4 ~mol/ml were below the 
level  of  significance;  i.e.,  1.5. 
8  days after challenge  with  25  ×  10 -4  /~mol of GP C1  and exposed in  vitro to 
concentrations  of GP  BP  and  rat  BP  from  2.5  to  125  ×  10 -4  /~mol/ml.  The 
parent  proteins  were  used  for in  vitro stimulation  in  these  particular  experi- 
ments, rather than the respective C1 peptide, since the results are comparable. 
Fig.  1B  shows  data  from rats  challenged  with  250  ×  10 -4  /~mol of rat  C1.  SI 
below 1.5 have been omitted from Fig.  1 since such values are below the  level 
of significance.  Comparison of the two curves in  Fig.  1A indicates  that  2.5  x KIBLER,  FRITZ,  CHOU,  CHOU,  PEACOCKE,  BROWN,  AND  McFARLIN  1327 
10  -4  $zmol/ml  of GP  BP  and  125  x  10  -4  izmol/ml  of rat  BP  gave  roughly 
comparable degrees of stimulation. In general, the in vitro response to the two 
BP was lower in Fig. 1B, but again the response to GP BP was greater. 
Antibody Response.  Groups of four rats each were challenged with GP and 
rat C1  at both 25  and 250  x  10  -4  /zmol in CFA in the same manner as that 
described for induction of EAE. A control group of four rats received CFA only. 
Sera were obtained from tail bleeds 9,  14,  23, and 35 days after challenge. All 
four experimental groups were boostered i.p. on day 38 with the respective C1 
peptide in IFA at the same dose as that used in challenge and the rats were 
exsanguinated 13 days later. All sera were tested for their capacity to bind 12~I- 
P1.  P1,  which contains tyrosine at residue 67,  was used instead of C1,  which 
contains histidine at position 87, since it was found that iodination of the latter 
residue interfered with the binding of certain anti-C1 sera. 
Fig. 2 shows the mean response of each group. In rats challenged with 25  x 
10  -4  fzmol of antigen, low levels of anti-GP C1 were first detected on day 23, 
followed by a  modest increase on day 35.  No appreciable levels of anti-rat C1 
were detected during this time. 13 days after an i.p. boost with the respective 
C1  peptide,  substantial levels of anti-GP C1  were achieved but there was no 
response to the boost with rat C1. At 250  x  10  -4/zmol there was a substantial 
and similar antibody response to the two peptides. The day-51 sera were tested 
for cross-reactivity and the  results  are  shown in Table  III.  Anti-GP C1  and 
anti-rat C1 reacted equally with the two labeled P1 fragments, suggesting that 
the two sets of sera recognized an antigenic determinant common to both C1 
peptides.  These  studies were  carried out  with  1:20 dilutions of the  antisera 
where binding was in the range of 50%. 
Discussion 
In the Le rat a heterologous peptide, GP C1, is substantially more encephalit- 
ogenic  than  the  homologous peptide.  This  presents  an  interesting paradox 
since T cells, which are the mediators of EAE (12), must presumably react with 
rat  C1  within the myelin sheaths of the central nervous system in order to 
initiate the lesions of EAE, regardless of which peptide is used in challenge. 
The difference in encephalitogenecity of GP and rat C1 is best explained by 
assuming that both peptides stimulate a  population of T  cells which have  a 
greater affinity for serine than for threonine at position 79; so that at compara- 
ble,  submaximal doses GP C1  stimulates a  greater number of cells than does 
rat C1.  The results of the in vitro lymphocyte stimulation assay presented in 
Table II and Fig.  1,  are consistent with this proposal.  These data show that 
LNC from rats challenged with either peptide were stimulated in vitro by both 
peptides, but in each instance the magnitude of the response was greater to GP 
C1.  An alternative explanation; i.e.  that blocking antibody accounts for the 
reduced encephalitogenecity of rat C1,  is not supported by the data shown in 
Fig. 2, since rat C1 was a less, rather than a more, potent inducer of antibody 
than was GP C1.  Other possibilities which seem less likely are that threonine 
79 in rat C1,  in addition to being a  part of the EAE determinant, is part of a 
suppressor site or, alternatively, that serine 79 in GP C1 is also part of a helper 
determinant for the induction of EAE. 1328  IMMUNE  RESPONSE  TO  PEPTIDE  68-88  OF  MYELIN  BASIC  PROTEIN 
400 
200 
D 
n.-  0  u_l 
Of) 
,_J 
:~  800 
121 
Z 
o  600  cn 
13- 
'u  400  0 
~E 
200 
0 
A  25  xlO-4pmol 
2  / 
I  ----Q .....  ~ .......  -o-"  : 
B  250 x 10-4..umol 
o 
I•S  • 
p. 
o- -  -  o"  BOOSTt 
,6  3'o  I/1 
DAYS  AFTER CHALLENGE 
FIo. 2.  Mean  antibody  response  to GP  (©) and rat (0) Cl of rats (four per group) 
challenged with 25 (A) and 250 (B) × 10  -4/~mol of  each peptide in CFA (250 ~g BMB/rat). 
The animals were bled by tail  at  the intervals  shown and boostered i.p.  on day 38 with the 
respective  CI in IFA at  the same dose as that used in challenge. They were exsanguinated 
on day 51. Antisera (diluted  1-10)  were tested  against the respective  I~5I-P1  (1 x 10  -7 M) by 
the sodium sulfate  method of  Day and Pitts  (7). 
TABLE  III 
Cross-Reactivity  of Anti-Cl Sera* 
Serum  Rat  125I-GP  PI  125I-Zat  P1 
Anti-GP C1 
pmol Pl bound/ml serum$ 
1  1,200  1,020 
2  1,280  1,240 
3  840  840 
4  860  960 
Avg.  1,045  1,015 
Anti-Rat C1  1  940  800 
2  1,080  940 
3  620  580 
4  540  580 
Avg.  795  725 
* Antisera are  from  rats  challenged and  boostered  with  250  ×  10  -4 
/~mol of the respective C1 (Fig. 2, Day-51 sera). 
Sera diluted 1:20 (~50% binding) and tested against I  ×  10  -7 M PI. KIBLER,  FRITZ,  CHOU,  CHOU,  PEACOCKE,  BROWN,  AND  McFARLIN  1329 
In this  system the in vitro  LNC  stimulation assay appears to measure a T- 
cell  response. Were B cells  primarily involved, we would not  have expected the 
marked difference in the response to the two peptides. The data in Table Ill 
indicate  that antibodies raised against either  peptide showed the same specific- 
ity for GP and rat C1, and it is generally assumed that receptors on B cells 
have the same specificity  as the antibodies they produce. Thus it  is more likely 
that the in vitro  LNC  response to the two peptides, which closely  paralleled 
their respective encephalitogenic  potencies, reflects  activity  of T cells,  which 
also  have a greater affinity  for serine than threonine at position  79. Our prior 
studies (3) have established that residue 79 is part of the EAE  determinant; 
but whether the determinant  responsible for in vitro LNC  stimulation is 
identical, or whether the same population of T cells  are involved in the two 
responses, will  require further study. The close  relationship  of  the  two activities 
demonstrated in this  study are at variance with the report by Spitler  et al. (13) 
which suggested that in guinea pigs,  it  was possible  to dissociate  production of 
EAE  from cell-mediated immunity  as measured by the in vitro  lymphocyte 
stimulation test.  In their  studies,  a synthetic peptide of  the active  tryptophan 
(residue 115)  region of  bovine BP was found to induce EAE  in guinea pigs but 
failed  to induce cell-mediated immunity. 
GP C1 also  had a significantly  greater  capacity to  stimulate the cells  involved 
in antibody production. This difference  was most apparent ai~er  the i.p.  boost 
in those groups of  rats  which received 25 × 10  -4 ftmol of  the respective peptide 
(Fig. 2A).  The antibody produced by either  peptide, however, reacted equally 
well with both peptides in the method of  RIA used in these studies (Table III). 
Fritz et al.  3  have recently shown that a high proportion of Le rat anti-GP C1 
sera bind,  or are competitively inhibited  by peptide 79-88 to  the same extent as 
peptide  C1;  but peptide  79-88  alone,  at  a  dose of 250  ×  10  -4  /~mol,  does not 
produce  antibody  even  after  an  i.p.  boost.  This  suggests  that  peptide  79-88 
contains  an  antigenic  determinant  which  reacts  with  antibody  but  which 
requires  a  T-helper  determinant  for  antibody  production.  Therefore,  despite 
the similarity  in  specificity of antibody produced by the two peptides,  GP C1 
produces more  antibody than  rat  C1  at the  low dose because it stimulates  a 
greater number of helper T cells. To decide whether or not the determinant for 
helper T-cell function is the same as the EAE determinant  will require more 
precise delineation of the two sites. 
Single amino  acid substitutions,  such as exist between GP and rat  C1,  are 
known  to  have  profound  effects  on  the  immunological  activity  of proteins. 
Allotype differences among the immunoglobulins, due to single isopolar substi- 
tutions,  show  up  readily  when  these  proteins  are  compared  by  antibodies 
produced to them.  Recently, Barcinski  and Rosenthal  (14) have shown that a 
serine (beef) interchange with glycine (sheep) in the alpha-loop region of the A 
chain  of insulin  caused  a  significant  difference  in  the  in  vitro  proliferative 
response of strain  2 GP.  Other  isopolar substitutions  within  this  region were 
found to have an effect on T-helper function. 
This study illustrates  the  manner  in which well-defined antigenic  prepara- 
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tions can be used to study immunological phenomena. A  19-amino acid peptide 
has been shown to induce EAE, produce circulating antibodies, stimulate LNC 
in vitro, and perhaps, stimulate helper T cells in the elaboration of antibodies. 
A  more precise delineation of the determinants and  of the  LNC  populations 
and/or  subpopulations  responsible  for  these  various  functions  may  answer 
some of the questions raised by this study. 
Summary 
Peptide C1  (residues 68-88) from GP and rat BP differ by a single amino acid 
interchange at residue 79. This residue is serine in GP C1 and threonine in rat 
C1. GP C1 was encephalitogenic in Le rats at doses as low as 15 ng. Rat C1 was 
encephalitogenic at  doses  of 1,500  ng  or greater.  LNC  from rats  challenged 
with  25  ×  10  -4  ~mol  of GP  C1  and  250  ×  10  -4  pmol  of rat  C1  showed  a 
proliferative  response  in  vitro  to  both  peptides,  but  in  each  instance  the 
magnitude of the response was greater to the GP peptide. GP C1 also induced 
higher levels of circulating antibodies at 25  ×  10  -4 ~mol, but the specificity of 
antibodies produced by the two peptides was the same. These results have been 
interpreted as indicating that the presence of serine at position 79  in GP C1 
results  in the  stimulation of greater numbers of T  cells involved in  (a)  the 
induction of EAE, (b) the in vitro proliferative response and (c) helper function 
in antibody production. 
Received for publication 15 June 1977. 
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